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ABSTRACT
The bleomycins (BLMs) are a family of natural
glycopeptides used clinically as antitumor agents.
In the presence of required cofactors (Fe
2+ and O2),
BLM causes both single-stranded (ss) and double-
stranded (ds) DNA damage with the latter thought to
be the major source of cytotoxicity. Previous bio-
chemical and structural studies have demonstrated
that BLM can mediate ss cleavage through multiple
binding modes. However, our studies have sug-
gested that ds cleavage occurs by partial intercala-
tion of BLM’s bithiazole tail 3’ to the first cleavage
site that facilitates its re-activation and re-organiza-
tion to the second strand without dissociation from
the DNA where the second cleavage event occurs.
To test this model, a BLM A5 analog (CD-BLM) with
b-cyclodextrin attached to its terminal amine was
synthesized. This attachment presumably precludes
binding via intercalation. Cleavage studies measur-
ing ss:ds ratios by two independent methods were
carried out. Studies using [
32P]-hairpin technology
harboring a single ds cleavage site reveal a ss:ds
ratio of 6.7±1.2:1 for CD-BLM and 3.4:1 and
3.1±0.3:1 for BLM A2 and A5, respectively. In con-
trast with BLM A5 and A2, however, CD-BLM
mediates ds-DNA cleavage through cooperative
binding of a second CD-BLM molecule to effect
cleavage on the second strand. Studies using the
supercoiled plasmid relaxation assay revealed a
ss:ds ratio of 2.8:1 for CD-BLM in comparison with
7.3:1 and 5.8:1, for BLM A2 and A5, respectively. This
result in conjunction with the hairpin results
suggest that multiple binding modes of a single
BLM can lead to ds-DNA cleavage and that ds
cleavage can occur using one or two BLM mole-
cules. The significance of the current study to
understanding BLM’s action in vivo is discussed.
INTRODUCTION
The bleomycins (BLMs, Figure 1) are a group of natural
glycopeptides produced by Steptomyces verticillus that
have potent antitumor activity against lymphomas, head
and neck cancers and testicular cancer (1–3). The BLMs’
therapeutic eﬃcacy is proposed to be related to their ability
to cause both single-stranded (ss) and double-stranded (ds)
DNA damage in the presence of the required cofactors
(Fe(II), O2 and a one-electron reductant) [(4–7); Figure 2].
The ds-DNA cleavage events have long been believed to be
the major source of BLMs’ cytotoxicity (8,9).
A model in which a single BLM molecule, which has a
single metal-binding site that can be activated for cleavage,
can eﬀect two cleavage events without dissociation from
DNA has been proposed by Povirk et al. (10). This model
was initially based on the analysis of ss to ds cleavage ratios
using the supercoiled DNA relaxation assay (11), which
revealed a constant ss:ds cleavage ratio (6:1) over a 20-fold
range of BLM concentrations. Povirk et al. also studied the
chemistry and sequence selectivity of the ds-DNA cleavage
by analyzing 30 ds-cleavage sites using native DNA gel
electrophoresis (10,12). These studies led to a set of
sequence selectivity rules for BLM-mediated ds-DNA
cleavage that could not be explained by two random ss
cleavage events (10).
Using the internally [
32P]-labeled hairpin DNA technol-
ogy to analyze the ss to ds cleavage products, Absalon
et al. conﬁrmed the sequence selectivity rules and extended
our understanding of the chemical mechanism for
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examined that contained a hot spot for ds cleavage
(50-GTAC-30, _ indicates the cleavage site), they estab-
lished a ss:ds ratio of 3.3 and that this cleavage ratio
remained constant over a 70-fold range of the BLM
concentrations (13). Furthermore, the ss:ds ratio was not
perturbed by the competitive binding of the chemically
unreactive BLM-Co(III)-OOH. This result supported the
model of a single BLM molecule eﬀecting ds-DNA
cleavage and precluded a model that involved cooperative
binding of a second BLM that mediated cleavage on the
second strand.
Structural models of BLM-Co(III)-OOH bound to
several oligonucleotides containing a single BLM-binding
site have been determined using 2D NMR studies (15,16),
which provided a working model to explain the mecha-
nismbywhichasingleBLMmoleculecaneﬀectds-cleavage
without dissociation from the DNA. This model requires
binding of the bithiazole tail of BLM by partial inter-
calation, 30 to the ﬁrst cleavage site. Subsequent to damage
initiation on the ﬁrst strand, the BLM molecule is
repositioned to the second strand by rotation of 1808
around the C-C bond connecting the two thiazolium rings
and by further rotation of 1178 around the axis per-
pendicular to the bithiazole ring (15). The mechanism of
triggering the re-organization to the second cleavage site
and the relative rate of this process to dissociation from
the DNA play a key role in identifying which sites are hot
spots for ds-cleavage.
Several studies using BLM analogs have demonstrated
that alternative binding modes to the partial intercalation
can lead to ss-DNA cleavage. BLM analogs with a
chlorinated bithiazole (Figure 1 in which either H5 or H50
of the bithiazole is substituted with chlorine atoms) were
shown to mediate a sequence-selective DNA cleavage
similar to BLM (17,18). In these studies, the chlorinated
bithiazole tail was shown to be located in the minor
groove of DNA by light-mediated DNA cleavage (18). An
additional independent study by the Hecht group has also
shown that BLM A5 tethered through its polyamine tail
to either controlled pore glass (CPG) beads (19,20) or a
dendrimer (21) can also cleave DNA. These attachments
were designed to be suﬃciently large to prevent binding of
the bithiazole tail by partial intercalation. The eﬃciency
and sequence selectivity of cleavage by these tethered
BLMs has been reported to be similar to that observed
with the untethered BLM, demonstrating that non-
intercalative modes of binding can also lead to DNA
cleavage (19–21). Unfortunately, the relationship of the
alternative binding mode to the mechanism of ds-DNA
cleavage was not quantitatively investigated in these
studies (19,21).
In this study, the signiﬁcance of the partial intercalation
in the model, to explain how one BLM molecule can aﬀect
ds-cleavage, is directly tested using a BLM A5 analog with
a b-cyclodextrin attached to the terminal amine (Figure 1).
This modiﬁcation is thought to be suﬃciently large to
prevent the binding of BLM by partial intercalation of
the bithiazole tail (22,23). The ability of CD-BLM to eﬀect
ds-DNA cleavage is reported using the internally
[
32P]-labeled hairpin DNA method (13) and the super-
coiled plasmid relaxation assay (11). The results indicate
that CD-BLM can mediate both ss- and ds-DNA cleavage
with the same sequence selectivity as BLM A5, although
5-fold less eﬃciently. The ss:ds cleavage ratio for
CD-BLM is determined to be 6.7±1.2:1 on the hairpin
DNA substrate, higher than the ratio for BLM A2 (3.4:1)
or A5 (3.1±0.3:1). Competition assays of the CD-BLM-
mediated ss- and ds-DNA cleavage in the presence of
Figure 1. Structures of BLM A2, A5, Phleomycin D1 (PLM),
chlorinated BLMs and CD-BLM.
Figure 2. Pathways of BLM-mediated DNA damage.
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the ds-DNA cleavage is mediated by two CD-BLM
molecules. Surprisingly, cleavage studies using the super-
coiled plasmid relaxation assay revealed a much lower
ss:ds cleavage ratio (2.8:1) for CD-BLM than for BLM A2
(7.3:1) or A5 (5.8:1). Furthermore, this ratio was not
aﬀected by chemically unreactive BLM-Co(III)-OOH.
The studies using two independent mechanisms to
examine the ss:ds cleavage ratios suggest that BLM can
mediate ds-DNA cleavage by multiple binding modes, not
just the partial intercalation binding mode that we
originally proposed.
EXPERIMENTAL SECTION
Materials
GT-2 (Figure 3) and its truncated primer containing the
ﬁrst 36 nucleotides (50-CGA ATT CTG CTG TAC ACT
TTC CCA AAA AGG GAA AGT-30) were synthesized by
Invitrogen Inc. on a 1mmol scale and were puriﬁed by
polyacrylamide gel electrophoresis (PAGE) (24). BLM A2
and A5 were purchased from CalBiochem in a metal-free
form. BLM-Co(III)-OOH (Co-BLM) was prepared and
puriﬁed as previously described (16). The concentration of
CD-BLM was determined by the extinction coeﬃcient at
292nm (14500M
 1cm
 1), assumed to be identical to
BLM A5. Escherichia coli DNA polymerase I-Klenow
Fragment (Klenow Fragment) was purchased from New
England Biolabs (1 U is deﬁned as the amount of enzyme
required to convert 10 nmol dNTPs into an acid-insoluble
form in 30min at 378C). T4 Polynucleotide Kinase (T4
PNK) was purchased from New England Biolabs (1 U is
deﬁned as the amount of enzyme to incorporate 1 nmol
acid-insoluble [
32P] in 30min at 378C). [g-
32P] Adenosine
triphosphate (ATP) (3000Ci/mmol) and [a-
32P] deoxy-
guanosine triphosphate (dGTP) (3000Ci/mmol) were
purchased from Perkin Elmer Life Sciences. b-cyclodex-
trin (2, Figure 4) and other chemicals were purchased from
Sigma-Aldrich. Mono-6-deoxy-6-amino-b-cyclodextrin
(5, Figure 4) was synthesized from 2 according to
published procedures (25). The yield and characterization
of each intermediate are summarized in the Supporting
Information. Dioxane was puriﬁed by reﬂuxing over KOH
followed by distillation from sodium. Proton NMR
spectra were measured on Bruker 400MHz or Varian
XL 500MHz spectrometers using tetramethylsilane
(TMS) as an internal reference at 0.00ppm.
Synthesis ofCD-BLM (1, Figure 4)
Synthesis of 6. Adipic acid monomethyl ester (5.23mg,
0.033mmol) was added to a solution of 5 (35mg,
0.031mmol, Supporting Information) in 0.6ml of
DMF. After the solution was cooled to  108C, dicyclo-
hexylcarbodiimide (7.6mg, 0.037mmol) and N-hydroxy-
benzotriazole (5mg, 0.037mmol) were added. The
resulting reaction mixture was stirring at room tempera-
ture for 24h. Insoluble materials were removed by
ﬁltration and 10ml acetone was added to the ﬁltrate.
The precipitate was collected and dried in vacuo to give
30mg of crude 6. The crude product (25mg) was dissolved
in n-butanol/ethanol/H2O (5:4:3) and 1g of silica gel was
added. The solvent was then removed in vacuo. The dried
silica gel with 6 absorbed was loaded on the top of a pre-
packed column (1.5 10cm). The compound was eluted
with the same solvent under pressure. Fractions contain-
ing 6 were pooled based on TLC [silica, n-BuOH/ethanol/
H2O (5:4:3)] and the solvent was then removed in vacuo to
give 23mg of 6 (70%).
1H NMR (400MHz, DMSO-d6, d):
6.07–5.61 (m, 14H, –OH at Positions 2 and 3), 4.94–4.73
(m, 7H, H1), 4.63–4.5 (m, 6H, –OH at Position 6), 3.81–
3.52 (m, 31H, H3, H5, H6 and –OCH3), 3.47–3.11
(m, overlaps with HOD, H2 and H4), 2.30–2.28 (m, 2H,
Ha), 2.20–2.08 (m, 2H, Hd), 1.58–1.30 (m, 4H, Hb and
Hc). ESI-MS (m/z): [M + H]
+ calcd. for C49H81NO37,
1276.4560; found, 1276.4565.
Synthesis of 7. NaOH (25.6ml of a 2M solution,
51.2mmol) was added to 0.8ml of dioxane/H2O (3:1)
containing 6 (39mg, 30.58mmol) and stirred at room
temperature for 6h. The reaction mixture was then
neutralized with glacial acetic acid andthe solvent removed
in vacuo. The crude product (40mg) was dissolved in 2ml
of water and was precipitated by adding 50ml of acetone
and further puriﬁed by C18 reverse-phase chromatography
(10ml). The column was washed with 100ml of H2O,
followed by 5% methanol/H2O. Fractions were collected,
pooled and solvent removed in vacuo to give 7 as white
solid (20mg, 52%).
1H NMR (400MHz, D2O, d): 5.05–
4.95 (m, 7H, H1), 3.95–3.68 (m, 27H, H3, H5 and H6),
3.60–3.45 (m, 13H, H2, H4), 3.40–3.3 (m, 1H, H4), 3.26
(dd, 1H, H6), 2.25–2.16 (m, 2H, Ha), 2.15–2.08 (m, 2H,
Hd), 1.59–1.45 (m, 4H, Hb and Hc). ESI-MS (m/z): [M –
H]
  calcd. for C48H78NO37, 1260.4247; found, 1260.4278.
Coupling 7 with Cu(II)BLMA5 to yield 8.N ,N-diisopro-
pylethylamine (0.51mg, 3.96mmol) and the BOP reagent
(0.88mg, 1.98mmol) were added to a solution of 7 (2.5mg,
1.98mmol) in 0.3ml of DMF at room temperature. The
reaction was stirred for 2min at room temperature and
then added to an anhydrous mixture of Cu(II)BLMA5
(1.98mmol) in 0.2ml of DMF at 08C. The reaction mixture
wasstirredat48Cfor36h.Solventwasremovedinvacuoto
give a blue product, which was further puriﬁed by reverse-
phase HPLC using an Econosil C18 column (Alltech,
10mm, 250mm   4.6mm). The elution involved a linear
gradient from 0 to 50% acetonitrile in 0.1M NH4OAc (pH
6.8) over 60min with a ﬂow rate of 1.0ml/min. Compound,
retention time, yield: 8, 27.8min, 0.95mmol, 48%;
Cu(II)BLMA5, 34.9min, 0.98mmol, 50%. ESI-MS
Figure 3. Sequence of GT-2. The predicted ss-cleavage sites of GT-2
are numbered. The G in bold denotes the internal [
32P] labeling site.
Nucleic Acids Research, 2008, Vol. 36, No. 11 3783(m/z): [M+2H]
2+ calcd. for C105H166N20O57S2Cu,
1372.9716; found, 1372.9767.
Synthesis of metal-free  -cyclodextrin-tethered BLM A5
(CD-BLM, 1). The copper complex of CD-BLM
(8, 0.81mmol) was dissolved in 0.6ml 15% Na2EDTA
(pH 4.65) and was stirred at 48C for 20h. The reaction
mixture was puriﬁed by RP-HPLC using an Econosil C18
column (4.6 250mm) with a linear gradient from 20 to
50% methanol in 0.1M ammonium acetate (pH 6.8) over
50minwithaﬂowrateof1.0ml/min.Compound,retention
time, yield: 1, 28.2min, 95%. The proton chemical shifts of
1 are summarized in Table S1. ESI-MS (m/z): [M + 2H]
2+
calcd. for C105H168N20O57S2, 1342.5146; found, 1342.5163.
Preparation of 50- and internal-[
32P] GT-2
(Figure 3). The 50- and internal-[
32P] GT-2 were synthe-
sized following the published procedure (13) and were
further puriﬁed by PAGE (24). The speciﬁc activity for
50-[
32P]-GT-2 was 2.1 10
6 cpm/mmol and for internal-
[
32P]-GT-2, was 2 10
7 cpm/mmol.
Cleavage of internal-[
32P] GT-2 by BLMs. The reaction
mixture of 80ml contained internal-[
32P] GT-2 (100000
cpm), 0.6mg/ml calf thymus DNA, 50mM NaCl and
50mM HEPES pH 7.5. Before adding BLM, the mixture
was heated to 958C for 2min in a heating block and was
cooled to 48C over 1h. BLM A5 or CD-BLM was
activated ex situ by mixing 500mM BLM with an equal
concentration and volume of iron(II) ((NH4)2Fe(SO4)2)
for 60±2s at 48C (13). For the reactions with low BLM
concentrations (2.5 to 10mM), the activation mixture was
diluted 10-fold with deionized water to make a 25mM
solution. For the reactions with high BLM concentrations
(10 to 50mM), the activation mixture was used without
further dilution. An appropriate aliquot of the activation
mixture (250mMo r2 5mM after dilution) was added to the
reaction mixture to achieve the desired ﬁnal concentra-
tion. The reaction mixture was incubated at 48C for
10min and was quenched by adding 50mlo f3MN H 4OAc
(pH 5.2) and 370ml ethanol at 48C. The solution was kept
at –808C for 1h and then centrifuged at 48C for 30min at
13000rpm. The supernatant was discarded and the pellet
was washed once by mixing with 1ml of 75% ethanol and
centrifuging for 30min at 13000rpm at 48C. The DNA
pellets were then dried in vacuo and dissolved in 10ml
DNA loading buﬀer [containing 90% formamide (v/v)].
In reactions that contained chemically inert Co-BLM,
the appropriate amount of Co-BLM was pre-mixed with
the activated BLMs before they were added to the ﬁnal
reaction mixture.
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Figure 4. Synthesis of CD-BLM (1).
3784 Nucleic Acids Research, 2008, Vol. 36, No. 11Quantitation of the DNA cleavage bands by ImageQuant
5.0. After the exposure of the sequencing gel to the
phosphorimage screen, the screen was scanned on a
Phosphoimager(ModelStorm840AmershamBiosciences).
The resolution of the scanning pixel was set to be 200mm.
The gel image was saved either as a GIF ﬁle for immediate
visualization or as a GEL ﬁle for the quantitative analysis.
The manufacturer’s software, ImageQuant 5.0, was used
to quantitate the intensity of the DNA bands in the gel.
The procedure of the quantitation has been described in
detail (13).
Relaxation of supercoiled plasmid DNA by BLMs. The
reaction mixture of 20ml contained 1mg pUC18 plasmid
DNA (2686bp, Stratagen, Supporting Information),
50mM HEPES, pH 7.5 and 0.2–0.8mM activated BLM.
The BLM was activated by mixing 50mM BLM (10ml)
with equal volume and concentration of iron(II). The
activation mixture was incubated at 48C for 1min. An
appropriate aliquot of the activated BLM was added into
the reaction mixture to achieve the desired ﬁnal concen-
tration. The reaction mixture was incubated at 48C for
10min and the reaction was quenched by adding 5mlo f
loading buﬀer containing 50% glycerol. In reactions that
contained Co-BLM, the appropriate amount of Co-BLM
was pre-mixed with the activated BLMs before they were
added to the ﬁnal reaction mixture.
The type I (supercoiled), II (nicked) and III (linear)
forms of plasmid DNA in the reaction mixture were
separated by 1% agarose gel electrophoresis in TBE buﬀer
containing 0.5mg/ml ethidium bromide at a constant
voltage of 80V for 90min. The bands were visualized
using a Bio-Rad ChemiDoc XRS UV-trans-illuminator
and were quantitated by the manufacturer’s software Bio-
Rad Quality One. The number of ss cleavage events (n1)
and ds cleavage events (n2) can be calculated from the
Poisson distribution (11): fI = e
–(n1+n2) and fIII=n2e
 n2.
(fI and fIII are fractions of the supercoiled and linear
plasmid, respectively).
RESULTS
Sequence-specific cleavage of GT-2 by CD-BLM
The internally [
32P]-labeled hairpin DNA technology
developed in our group has enabled us to quantitate the
site-speciﬁc ss and ds cleavage simultaneously in a deﬁned
sequence context (13,14). The hairpin DNA sequence used
in this study, GT-2, contains a ‘hot spot’ for ds-DNA
cleavage by BLM (T13 and T38 in the 50-GTAC-30
sequence indicated in the box in Figure 3, where T denotes
the cleavage site), as well as several additional good
ss-cleavage site, including C10, C43 and T36 (Figure 3)
(13). The ss- and ds-DNA cleavages of internally labeled
GT-2 by BLM result in DNA fragments with character-
istic lengths for each cleavage site (Table 1), which can be
separated and quantitated using the DNA sequencing gel
electrophoresis (13).
The results of the cleavage study of the internal-[
32P]
GT-2 using various concentrations of CD-BLM
(0–50mM) are shown in Figure 5. Quantitative analysis
of the cleavage product intensity at each ss-cleavage site
indicates that the amount of the ss-cleavage product
increased linearly with the concentration of CD-BLM
(Figure S1) and is consistent with ‘single-hit’ conditions.
The intensities of cleavage products mediated by 50mM
CD-BLM (Lane 6 in Figure 5) are analyzed in Figure 6B
and are compared to the cleavage patterns by BLM A5
(7.7mM BLM A5, Figure 6A). Under these assay
conditions, 50mM CD-BLM produced approximately
the same extent of overall cleavage (12%) as 7.5mM
BLM A5 (10%), indicating that CD-BLM is at least 5-fold
less eﬃcient in the cleavage of GT-2 than BLM A5. The
reduced overall DNA cleavage ability could be attributed
to the b-cyclodextrin group, which would be expected to
reduce the aﬃnity of CD-BLM for DNA. It might also be
Table 1. Distribution of the cleavage products of GT-2 by BLMs and
CD-BLM
Cleavage site Predicted
length
50-terminal 30-terminal Observed
length
C10ss 41 Phosphate OH 42–43
C43ss 42 OH Phosphoglycolate
(PG)
42–43
T13 38 Phosphate OH 39
T36 15 Phosphate OH 16
T38 37 OH PG 37–38
A32 19 Phosphate OH 20
(T13+T38) ds 24 phosphate PG 25
Figure 5. Cleavage of internal-[
32P] GT-2 by CD-BLM analyzed by
PAGE. Lane 1: Maxim-Gilbert G+A reaction. Lane 2–5: 0, 12.5, 25,
37.5, 50mM CD-BLM.
Nucleic Acids Research, 2008, Vol. 36, No. 11 3785related to a slower rate to generate activated BLM and/or
a faster degradation rate of the activated species,
CD-BLM-Fe(III)-OOH.
Although CD-BLM is less eﬃcient in overall DNA
cleavage than BLM A5, the results reveal similar sequence
speciﬁcity of ss-DNA cleavage (Figure 6). Thus, the bulky
b-cyclodextrin group and its presumed hindrance to
intercalation, do not seem to interfere with its ability to
form H-bond interaction with G, 30 to the pyrimidine
cleavage site which is suggested to be the basis of
speciﬁcity by solution NMR structural studies (16).
The relative intensities of the cleavage products at each
ss cleavage site (T13, T13, C10, C43, A32 and T36 of GT-2)
for CD-BLM are also quite similar to those for BLM A5
(Figure 6) and the previously studied BLM A2 (13). The
predominant cleavage sites are T13 and T38, with C10/C43
>> T36 > A32. A notable diﬀerence between CD-BLM
and BLM A5 is the relative intensity at T13 and T38.
CD-BLM produced almost equal amounts of cleavage
products at these two sites, while BLM A5 and A2 (13)
cleaved the T38 site with twice the eﬃciency relative to the
T13site(Figure6).Thediﬀerenceofthecleavageintensities
between T13 and T38 for natural BLMs was used by
Absalon et al. to suggest that T38 might be the primary
ss-cleavage site for initiating ds-DNA cleavage (13).
The change of the relative cleavage intensity at T13 and
T38 for CD-BLM suggests that CD-BLM is capable of
initiating ds-DNA cleavage from either strand (see the
discussion below).
Chemistry of cleavage by CD-BLM. As shown in
Figure 2, BLMs have been shown to mediate direct
strand cleavage resulting in 30-phosphoglycolate/50-phos-
phate ends. Gel analysis reveals that cleavage products by
CD-BLM are the same as those observed with BLM A5
(Figure 6) and that 30-phospholycolate ends are generated
at the same sites (Table 1). Thus, while the chemistry of
CD-BLM mediated cleavage has not been studied in
detail, 40-chemistry is strongly implicated.
Site-specific ds-DNA cleavage mediated by CD-BLM. In
addition to ss-DNA cleavage, CD-BLM also mediated
ds-DNA cleavage at T13 and T38 (Figures 5 and 6). The
percentage of ds-DNA cleavage increased linearly with the
CD-BLM concentration (ﬁlled circles in Figure S2). The ss
to ds cleavage ratio at T13 and T38 sites was determined
in triplicate to be 6.7±1.2, which is higher than the ratio
for BLM A2 (3.4) or A5 (3.1±0.3) in the same sequence
context (13). The ss to ds cleavage ratios for CD-BLM
at T13 and T38 remained constant over the range of
12.5–50mM CD-BLM (Figure 7). This result indicates that
theobservedds-DNAcleavageatT13andT38cannotarise
from two coincidental ss cleavage events, which would lead
to more ds-cleavage at higher CD-BLM concentrations.
ThesstodscleavageratiobyCD-BLM(6.7±1.2)isboth
statistically and mechanistically signiﬁcant. The separation
of the T13 and T38 ss cleavage bands (Figure 5) allows the
quantitative estimation of the amount of ds-cleavage due
to two coincidental ss-cleavage events. The calculated
random ds-cleavage percentages at diﬀerent CD-BLM
concentrations are plotted in Supporting Figure S2 (ﬁlled
squares, Figure S2), which are much lower than the
Figure 6. Quantitation of ss- and ds-cleavage products of internal-[
32P]
GT-2. (A), by 7.5mM BLM A5; (B), by 50mM CD-BLM.
Figure 7. The concentration dependence of %ss-cleavage versus
%ds-cleavage at T13 and T38 by CD-BLM.
3786 Nucleic Acids Research, 2008, Vol. 36, No. 11observed ds-cleavage. At 50mM CD-BLM, the percentages
of ss-cleavage at T13 (2.01%) and T38 (2.44%) give rise
to the calculated random ds-cleavage of 0.054%
(2.01 2.44%), 17 times lower than the observed ds
cleavage (0.92%).
The total extent of cleavage under the above conditions
is 3.3 to 14% (12.5–50mM CD-BLM). To investigate
whether the observed ss to ds cleavage ratio would change
under conditions of <1% overall cleavage, additional
studies were carried out in the presence of calf thymus
DNA present in increasing amounts from 0.6 to 5mg/ml.
The cleavage reaction mixture was analyzed by the DNA
sequencing gel and is shown in Figure S3. The overall
cleavage at 20mM CD-BLM is 0.6%. The ss to ds cleavage
ratio determined in this experiment, 7.8±2.4, (in a
separate measurement, 7.3±1.4) is consistent with our
previous studies (6.7±1.0). This result, together with the
concentration-independent ss:ds cleavage ratio, suggests
that the ds-DNA cleavage by CD-BLM is mediated either
by a single CD-BLM molecule, or by the cooperative
binding of a second CD-BLM.
Ds-cleavage of GT-2 by CD-BLM is mediated through
cooperative binding. To distinguish between these two
models, the cleavage of internal-[
32P]-GT-2 by CD-BLM
was further investigated in the presence of the chemically
inert BLM-Co(III)-OOH (Co-BLM). In previous studies
by Absalon et al. (14), this competition assay was carried
out to provide additional support for the model that a
single BLM molecule can mediate ds-DNA cleavage. The
ss to ds cleavage ratio is determined by the relative rate of
dissociation of BLM versus re-organization after the
chemistry at the ﬁrst cleavage site. Thus, the single mole-
cule model predicts that the presence of the Co-BLM, a
chemically inert inhibitor, would compete with the BLM
for binding and consequently, aﬀect ss and ds cleavage to
the same extent. Thus, the ratio of ss:ds cleavage would
remain unchanged. However, if the chemistry at the ﬁrst
site promotes cooperative binding of a second BLM
molecule to the second site, then Co-BLM would be
expected to hinder ds-cleavage more than ss-cleavage.
Thus, the ss:ds cleavage ratio would increase.
The cleavage of the internal-[
32P] GT-2 by CD-BLM
was analyzed by DNA sequencing gel (Figure 8) in the
presence and absence of various amounts of Co-BLM.
Co-BLM suppressed cleavage at both ss- and ds-cleavage
sites. However, the ds-cleavage was aﬀected much more
than the ss-cleavage. This eﬀect is clearly demonstrated by
quantitatively analyzing Lane 4, 7 and 10 in Figure 8 (Line
graph A, B and C in Figure 9). The ss to ds cleavage ratio
increases from 7.3±1.4 (no Co-BLM) to 12.5±2.5 (0.25
equivalent Co-BLM) and 21±14.2 (0.5 equivalent
Co-BLM) (Table 2). Furthermore, The ss to ds cleavage
ratio measured with 0.5 equivalent Co-BLM is close to the
lower limit of detection (compare the intensity of the
T13+T38 ds-cleavage product with background in Line
graph C, Figure 9).
ControlexperimentsusingBLMA5werealsoperformed
with 0 or 5 equivalent of Co-BLM (Lane 11 and 12 in
Figure 8) with quantitative analysis shown in Line graph D
and E, Figure 9. The ss to ds cleavage ratio remains
Figure 8. Competitive inhibition of CD-BLM-mediated DNA cleavage
by Co-BLM. Lane 1: Control. Lane 2–4: 5, 10, 20mM CD-BLM. Lane
5–7: 5, 10, 20mM CD-BLM with 0.25 equivalent Co-BLM. Lane 8–10:
5, 10, 20mM CD-BLM with 0.5 equivalent Co-BLM. Lane 11: 5mM
BLM A5. Lane 12: 5mM BLM A5 with ﬁve equivalents Co-BLM.
Figure 9. Quantitation of CD-BLM mediated cleavage and its
attenuation by BLM-Co(III)-OOH. (A), 20mM CD-BLM; (B), 20mM
CD-BLM+5mM Co-BLM; (C), 20mM CD-BLM+10mM Co-BLM;
(D), 5mM BLM A5; (E), 5mM BLM A5+25mM Co-BLM.
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Co-BLM compared to BLM A5 alone (3.1±0.3). These
results indicate that CD-BLM mediates ds-DNA cleavage
by cooperative binding of a second CD-BLM molecule
afterchemistry at theﬁrst site. BLMA5, onthe otherhand,
mediates ds-cleavage by a single BLM molecule, consistent
with previous studies on BLM A2 (14).
Ss:ds cleavage ratio determined by the supercoiled plasmid
relaxation assay. The supercoiled plasmid relaxation
assay has been widely used to determine the ss to ds
cleavage ratios by BLM (11,26–28). The number of the ss
and ds cleavage events can be calculated from the fraction
of Type II (relaxed) and Type III (linear) plasmid forms
generated under single-hit conditions using the Poisson
distribution described in the experimental section (11).
CD-BLM is shown to mediate ds-DNA cleavage using
the supercoiled plasmid relaxation assay (Figure S4).
CD-BLM showed 50% of the cleavage eﬃciency compared
to BLM A5 using this assay. The UV densitometry analysis
ofthegelispresentedinFigureS5.Surprisingly,thesstods
cleavage ratio determined for CD-BLM is 2.8 to 1, lower
than that observed for BLM A5 (5.8 to 1) or A2 (7.3 to 1).
For comparison, PLM, which is a poor ds-cleavage agent,
shows a ss:ds ratio of 47 to 1. In contrast to results from the
hairpin DNA cleavage studies, the ss to ds cleavage ratio
for CD-BLM remained unchanged in the presence of
Co-BLM (Figure S6, Lane 3 and 4), suggesting that the
observedds-DNAcleavageofsupercoiledplasmiddoesnot
resultfromcooperativebindingofasecondBLMmolecule.
However, the mechanistic interpretation of these ratios is
complicated by the lack of understanding of molecular
details on the interaction between CD-BLM and super-
coiled plasmids (see the discussion below).
DISCUSSION
In the present study, b-cyclodextrin was used as a bulky
attachment to the terminal amine group of BLM A5 to
preclude the intercalation of the bithiazole tail.
b-Cyclodextrin was chosen based on its size [6A ˚ (height)
by 12A ˚ (diameter), PDB ID 3CGT] (22), its water-soluble,
non-ionic nature and a facile route to its synthesis. This
molecule could be characterized by NMR spectroscopy in
contrast to the controlled-pore glass beads or dendrimers
used for a similar purpose in previous studies (19,21).
Although we argue that b-cyclodextrin is suﬃciently large
to prevent intercalation, we have been unable to
demonstrate the mode(s) of CD-BLM binding to DNA.
However, based on the inhibition of DNA cleavage
by Co-BLM (Figure 8), we can estimate that activated
CD-BLM binds to GT-2at least 10 times weaker than
BLM A5. This observation is inconsistent with a slow
dissociation rate predicted for threading intercalation of a
bulky intercalator (29).
The classic method to demonstrate intercalation is to
study the unwinding of the supercoiled DNA using
agarose gel electrophoresis (30). Technically, this method
would require that CD-BLM be incorporated into the gel.
This incorporation would require larger amounts than are
available. In addition, this method is not capable of
detecting weak intercalators or intercalators that bind at a
limited number of intercalation sites. For example, earlier
results from studies with PLM using this method were
interpreted to indicate a non-intercalative binding mode
(31–33). However, our NMR spectroscopic analysis of
PLM with oligonucleotides containing a single binding
site (50-GTAC-30) indicates that PLM can intercalate,
although it is in fast exchange between the free and DNA-
bound states (34).
The quantitative analysis of CD-BLM-mediated DNA
cleavage gives a ss:ds cleavage ratio of 6.7±1.2:1, which is
signiﬁcantly higher than that of BLM A5 and A2 under the
same assay conditions. A key aspect of the quantitation is
the background level of cleavage due to a combination of
non-speciﬁc cleavage possibly by hydroxyl radicals gener-
ated byCD-BLMs (35,36), radiation damage of GT-2from
[
32P] decay, and/or spontaneous depurination. The non-
speciﬁc cleavage by CD-BLM is likely the major source of
the background because the amount of the non-speciﬁc
cleavage increases with the CD-BLM concentration
(Figures 5 and S3). When the overall cleavage is less than
1% as in Figure S3, the random ds cleavage at T13 and T38
is estimated to be approximately 0.002%, far less than the
background, which is usually 0.01%. Thus, background
cleavage sets the limit of detection for the ss to ds cleavage
ratio to be  20:1. The previously observed limit of
detection by Absalon et al. (14) was  7:1 with 7% overall
cleavage, which was largely determined by ds-cleavage
generated by two random ss-cleavage events.
The cooperative binding model of CD-BLM-mediated
ds-cleavage requires the potentiation of binding of second
CD-BLM molecule after chemistry at the ﬁrst site. This
model predicts that CD-BLM would have a higher aﬃnity
for ss-lesioned DNA (not necessarily cleaved), than for the
intact DNA. The identity of the ss-lesioned DNA that is
Table 2. Quantitation of CD-BLM-mediated cleavage of GT-2. Column A-E corresponds to line-graphs A-E in Figure 9
Assay
Condition
AB C D E
20mM CD-BLM 20mM CD-BLM+
5mM Co-BLM
20mM CD-BLM+
10mM Co-BLM
5mM BLM A5 5mM BLM A5+
25mM Co-BLM
ss (T13+T38) 438
a 366 259 668 124
ds (T13+T38) 72.3 46.1 27.3 213 33.7
Average background 13 17 15 12 13
ss to ds ratio 7.3±1.4 12.5±2.5 21±14.2 3.1±0.3 3.6±0.9
aArbitrary unit.
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this stage. The 30-phosphoglycolate/50-phosphate lesion
(30-PG/50-P) (Figure 2) was shown to be present at the ﬁrst
cleavage site in all BLM-mediated ds-cleavage and might
play a role in recruiting the second CD-BLM (37). Our
studies have shown that the chemistry of 30-PG/50-P
production is complex (38,39). The NMR analysis of
Burger et al. is often cited as evidence against 30-PG/50-P
being a prerequisite for BLM binding to the second strand,
due to its slow formation. Using the 50-(CAAGCTTG)2-30
and looking at 50-P formation with
31P NMR, they showed
that on average, this 30-PG/50-P lesion was generated on a
minutetimescale(40).However,itislikelythatathotspots
for ds-cleavage, the kinetics of 30-PG/50-P generation could
be dramatically altered relative to the more prevalent ss
cleavage sites. Thus, the structural basis for cooperative
binding of a second BLM remains unknown.
The results from internal-[
32P] hairpin cleavage studies
demonstrate that partial intercalation of the bithiazole tail
is required for ds-DNA cleavage mediated by a single
BLM. This is consistent with our proposed model based
on the sequence selectivity (10,12), chemistry of the
ds-cleavage at a hot spot (50-GTAC-30) (14) and structural
studies on a complex of BLM-Co(III)-OOH bound to
this hot spot (15). However, the eﬃcient ds-cleavage by
CD-BLM on supercoiled plasmid suggests that our model
could be over-simpliﬁed. The unusually low ss:ds cleavage
ratio compared with BLM A2 and A5 suggests that there
might be other unknown hot spots in supercoiled plasmid
that allow CD-BLM to mediate eﬃcient ds-cleavage
without partial intercalation or cooperative binding. Neg-
ative supercoiling in plasmid DNA is known to induce a
variety of secondary structures, including A-form, cruci-
forms, and left-handed DNA (41). BLM has been shown to
cleave at the junction of tRNA secondary structures
(42,43). Therefore, the results from the two independent
cleavage studies support multiple binding modes of BLM
that can result in ds-DNA cleavage depending on the
structures and conformation of the DNA substrates.
It is crucial to determine which binding modes by
natural BLMs are essential for their cytotoxicity and
therapeutic eﬃcacy. Unfortunately, neither hairpin DNA
nor supercoiled plasmid is a good model system for
studying DNA damage in vivo. Povirk et al. has shown
that in vitro, partial intercalation is required for BLM-
mediated ds-DNA cleavage in reconstituted nucleosomes
(44). The in vivo concentration of BLMs is another
important piece of puzzle to answer this question. If the
concentration of BLMs inside the nucleus is low, ds-DNA
cleavage by cooperative binding of a second BLM would
be highly unlikely, and it would argue in favor of the
single-BLM cleavage model requiring partial-intercala-
tion. At present, it is not clear how eﬃcient BLMs are
taken up into the cell or into the nucleus. Studies using
mammalian cell lines (45,46) or yeast (47,48) suggest that
BLMs enter the cell via a deﬁned pathway involving cell
surface receptors and endocytosis. However, previous
methods using radiolabeled BLMs failed to provide a clear
answer to the in vivo concentration of BLMs due to the
chemical reactivity of the labeled methyl group of the
dimethylsulfonium tail of BLM A2 [(49–51); Figure 1].
In vivo studies using stable radio-labeled BLMs are under
way to elucidate the uptake and localization of BLMs
inside the cell. The information from in-vivo studies,
together with our mechanistic understanding of BLM-
mediated DNA cleavage, could potentially lead to better
BLM therapeutics with lower toxicity.
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